Skip to content
Biodatica
Start free

Janssen Pharmaceutical K.K.

Anjo-shi

OncologyPhase IIIListed · JNJ

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

6w agoTrial registeredJun 5, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Momentum 82 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Feb 22, 2021

    Hematologic Malignancies · COMPLETED · sponsor: Janssen Pharmaceutical K.K. · A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

    ClinicalTrials.gov · NCT04696809 (opens the source filing in a new tab)

  2. Trial

    PHASE2/PHASE3 registered

    Jan 8, 2021

    Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) · COMPLETED · sponsor: Janssen Pharmaceutical K.K. · A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

    ClinicalTrials.gov · NCT04630145 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Sep 28, 2018

    Healthy · COMPLETED · sponsor: Janssen Pharmaceutical K.K. · A Study of JNJ-63733657 in Healthy Japanese Participants

    ClinicalTrials.gov · NCT03689153 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    May 1, 2018

    Graft vs Host Disease · COMPLETED · sponsor: Janssen Pharmaceutical K.K. · A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

    ClinicalTrials.gov · NCT03474679 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources